Education
About Us
Working with TipRanks
Follow Us
Esperion (GB:0IIM)
LSE:0IIM
Earnings Data
Report Date
Nov 05, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
0.02Last Year’s EPS
-0.15Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance with significant growth in U.S. sales, successful marketing campaigns, and progress in international markets. The company's strategic initiatives are leading to increasing revenue and market penetration. Despite a decrease in collaboration revenue, the positive developments and future prospects significantly outweigh this lowlight.Company Guidance -
Q3 2025
Strong U.S. Net Product Sales Growth
U.S. net product revenue grew 42% year-over-year to $40.3 million and 15% sequentially from the first quarter of 2025.
Record Operating Income
Achieved operating income from ongoing business of approximately $15 million, marking the first quarter of operating income in the company's history.
Successful Marketing Campaigns
The 'Can't take a statin? Make NEXLIZET happen' campaign and digital omnichannel programs significantly increased brand awareness, with more than 650,000 visits to the consumer website and a 10% increase in total retail prescription equivalents.
Expansion in European Market
Royalty revenue from Daiichi Sankyo Europe increased 30% from Q1 2025 to $13.6 million, with over 500,000 patients treated in Europe.
Advancements in Pipeline and Partnerships
Progress in developing a triple combination product and settlement agreements with generic manufacturers to protect NEXLETOL from generic competition until 2040.
International Expansion
Progress in Japan, Canada, Israel, and Australia with expected market approvals and milestone payments in the near future.
GB:0IIM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0IIM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 05, 2025 | $1.47 | $1.62 | +10.58% |
May 06, 2025 | $1.04 | $0.96 | -8.08% |
Mar 04, 2025 | $1.60 | $1.79 | +12.26% |
Nov 07, 2024 | $2.19 | $2.12 | -3.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Esperion (GB:0IIM) report earnings?
Esperion (GB:0IIM) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).
What is Esperion (GB:0IIM) earnings time?
Esperion (GB:0IIM) earnings time is at Nov 05, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Esperion stock?
The P/E ratio of Esperion is N/A.
What is GB:0IIM EPS forecast?
GB:0IIM EPS forecast for the fiscal quarter 2025 (Q3) is 0.02.